Weighting Cancer Drugs To Make Them Hit Tumors Harder
Duke scientists have devised a blueprint for boosting anti-cancer drugs' effectiveness and lowering their toxicity by attaching the equivalent of a lead sinker onto the drugs. This extra weight makes the drugs penetrate and accumulate inside tumors more effectively.
Source: www.sciencedaily.com
Newer Diabetic Meds Cost More, But Users Have Fewer Hospital Visits
Diabetics who were prescribed newer medications to control their illness were more likely to take these drugs as instructed than were other patients who were prescribed drugs that have been on the market for several decades. A new study suggests that patients on the newer medications had a slightly lower risk of hospitalization because of diabetes-related complications. They also spent between
Source: www.sciencedaily.com
Staff Writer
A research collaboration that started in August 2003 came full circle this week when French company NicOx SA granted Merck & Co. Inc. exclusive worldwide development and marketing rights to nitric oxide-donating drugs for hypertension.
Source: www.bioworld.com
British Mishap Tests Clinical-Trial Safety
By CHRISTINE DELL'AMORE A clinical trial gone wrong in Britain this month has some concerned about the safety of such trials, but advocates say they are the sole vehicle for developing new treatments.
Source: www.redorbit.com
Many Drug Companies Changing Product Advertisements To Head Off FDA Concerns
The AP/Arizona Daily Star on Tuesday examined how the voluntary advertising guidelines adopted by the pharmaceutical industry "have ... sparked changes" after the industry faced a "furor over its advertising practices and the potential of more government regulation." The voluntary guidelines, adopted in January, have "improve[d] the accuracy and balance of ads so the severity of diseases and
Source: www.medicalnewstoday.com
Neuromed strikes major Merck deal
Neuromed Pharmaceuticals Ltd. , a closely held, eight-year-old biotech spinoff from the University of British Columbia, has struck a drug research deal valued at up to $500-million (U.S.) with giant Merck & Co. Inc.,
Source: www.globeinvestor.com
Merck takes the offensive in Atlantic City, N.J., trial
ATLANTIC CITY, N.J. - After two weeks on the defensive, Merck & Co. began presenting its side of the Vioxx story to a jury Tuesday, hoping to show that the popular arthritis drug was thoroughly tested before being sold and didn't cause the heart attacks suffered by two New Jersey men.
Source: www.phillyburbs.com
FDA panel advises stronger warnings for ADHD drugs
Hallucinations reported with use; most drastic label rejected A Food and Drug Administration advisory panel urged yesterday beefed-up warnings for drugs used to treat attention deficit disorder after hearing about hundreds of cases in which children using the medications experienced frightening hallucinations, often involving bugs and snakes.
Source: feeds.baltimoresun.com
